Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GlycoMimetics
Biotech
Crescent inks GlycoMimetics merger, securing listing and $200M
Crescent is part of the pack of drug developers targeting the PD-1xVEGF bispecific opportunity.
Nick Paul Taylor
Oct 29, 2024 10:20am
GlycoMimetics fails phase 3 blood cancer trial, sinking stock
May 6, 2024 8:11am
Homology shakes up leadership—Chutes & Ladders
Sep 9, 2022 9:30am
Pfizer cuts GlycoMimetics pact as Merck axes KalVista deal
Feb 11, 2020 7:45am
GlycoMimetics hit as Pfizer-partnered phase 3 drug flops
Aug 5, 2019 9:55am
